GST HG121
Alternative Names: GST-HG121Latest Information Update: 18 Oct 2022
At a glance
- Originator Fujian Akeylink Biotechnology
- Class Antivirals; Carboxylic acids; Oxazepines; Small molecules
- Mechanism of Action Hepatitis B surface antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hepatitis B
Most Recent Events
- 18 Oct 2022 Chemical structure information added
- 19 Jul 2022 Phase-I clinical trials in Hepatitis B (In volunteers) in China (PO)(NCT05576584)
- 27 Aug 2020 State Drug Administration approves clinical trial application for GST HG121 in Hepatitis B virus infections